

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.203/02/2015
900317357

ETAS ID: TM333780

SUBMISSION TYPE:		NEW ASSIGNMENT	
NATURE OF CONVEYANCE:		ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL	
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Micropharma Limited		11/28/2014	COMPANY: CANADA
RECEIVING PARTY DATA			
Name:	UAS Laboratories LLC		
Street Address:	555 N. 72nd Avenue		
City:	Wausau		
State/Country:	WISCONSIN		
Postal Code:	54401		
Entity Type:	LIMITED LIABILITY COMPANY: WISCONSIN		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Serial Number:	77890791	CARDIOVIVA	
CORRESPONDENCE DATA			
Fax Number:			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	414-431-0032		
Email:	marjory@marjorstewart.com		
Correspondent Name:	Marjory S. Stewart		
Address Line 1:	750 N. Lincoln Memorial Drive		
Address Line 2:	Suite 312		
Address Line 4:	Milwaukee, WISCONSIN 53202		
ATTORNEY DOCKET NUMBER:	UAS TM ASSIGNMENT		
NAME OF SUBMITTER:	Marjory S. Stewart		
SIGNATURE:	/Marjory S Stewart/		
DATE SIGNED:	03/02/2015		
Total Attachments: 5			
source=Redacted UAS TM#page1.tif			
source=Redacted UAS TM#page2.tif			
source=Redacted UAS TM#page3.tif			
source=Redacted UAS TM#page4.tif			

OP \$40.00 77890791

**ASSIGNMENT OF TRADEMARKS AND
TRADEMARK REGISTRATION RIGHTS**

WHEREAS, Micropharma Limited, a company organized under the laws of Canada (the "Company"), is the owner of the trademark applications and registrations set forth on the attached Exhibit A (the "Marks") for the trademarks the Company or its predecessor(s) in interest has adopted, has used, is using, or has an intent-to-use; and

WHEREAS, pursuant to that certain Asset Purchase Agreement, dated as of November 28, 2014, between UAS Laboratories LLC, a Wisconsin limited liability company ("Buyer") and the Company (the "Purchase Agreement"), Buyer has agreed to acquire from the Company, and the Company has agreed to transfer to Buyer, all of the Company's right, title and interest in and to the Marks along with other rights which fall within the scope of "Business Intellectual Property Rights" under the Purchase Agreement (such common law trademarks, service marks and trade names and the Registered Trademarks are collectively referred to as the "Trademarks").

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company hereby sells, assigns and transfers to Buyer and its successors and assigns the Company's entire right, title and interest in and to, and the use of, the Marks and all renewals thereof, together with (a) the goodwill of the business symbolized by the Marks and (b) all claims and demands that the Company (either itself or through its predecessor(s)) may have, at law or in equity, whether presently known, unknown, accrued or to accrue, arising out of past or present infringements of the Marks, including, without limitation, the right to recover all claims for damages and compensation. Such right, title and interest shall be held and enjoyed by Buyer and its successors and assigns as fully and entirely as the same would have been held and enjoyed by the Company if this sale, assignment and transfer had not been made.


The provisions of this instrument are subject, in all respects, to the terms and conditions of the Purchase Agreement, including, without limitation, all of the covenants, representations and warranties contained therein, all of which shall survive the execution and delivery of this instrument to the extent indicated in the Purchase Agreement. Nothing contained in this instrument shall be deemed to modify, amend or supersede any of the terms or conditions of the Purchase Agreement. In the event of any conflict or inconsistency between the terms and conditions of this instrument and the terms and conditions of the Purchase Agreement, the terms and conditions of the Purchase Agreement shall prevail. This instrument shall be binding upon the Company and its successors and assigns, and shall inure to the benefit of Buyer and its successors and assigns.

[Signature page follows]

IN TESTIMONY WHEREOF, the Company has caused its duly authorized officer to execute and deliver this instrument as of November 28, 2014.

MICROPHARMA LIMITED

By: _____
Name: Ryan Jones
Title: CEO




Before me, a notary of the province of Ontario, personally appeared Ryan Jones, with whom I am personally acquainted (or proved to me on the basis of satisfactory evidence) and who, upon oath, acknowledged that such person is a duly elected, qualified and acting officer of Micropharma Limited and that such person executed the foregoing instrument for the purposes described therein, by signing the name of the corporation by such person as a duly elected, qualified and acting officer.

IN WITNESS HEREOF, I hereunto set my hand and seal of my office on November 28, 2014.

(Seal)

My Commission Expires: N/A



Notary Public

EXHIBIT A

MARKS

Trademark	Country	Application Number	Registration Number	Goods	Status	Deadlines
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]


Error! Unknown document property name.

Trademark	Country	Application Number	Registration Number	Goods	Status	Deadlines
[REDACTED]	[REDACTED]		[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
CARDIOVIVA	USA	77/890791	4549592	Class 1, 5	Registered	Declaration of use 2019 Renewal due June 17, 2024
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]
[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]	[REDACTED]

[REDACTED]

1. [REDACTED]
2. [REDACTED]
3. [REDACTED]
4. [REDACTED]
5. [REDACTED]
6. [REDACTED]
7. [REDACTED]
8. [REDACTED]
9. [REDACTED]
10. [REDACTED]
11. [REDACTED]

Error! Unknown document property name.



Error! Unknown document property name.

5